Samaritan Files Provisional Patent to Support Promising New Type of Anti-cholesterol Drug SP-1000 and Cover Additional Claims;

Samaritan Pharmaceuticals Inc. (AMEX:LIV):

   --  Clears Clogged Arteries

   --  Raises HDL

   --  Reduces CK Enzyme Marker: Suggesting It Improves,
        Hypercholesterolemia-Related Heart Suffering, Which Commonly
        Leads to Heart Attacks

   Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of
innovative drugs, announced today, it has filed a new provisional U.S.
patent application to support its original application, and add
additional claims, for its cardiovascular drug SP-1000 for the
prevention and treatment of cardiovascular disease.
   Samaritan's collaborating scientists, through animal studies,
validated SP-1000's ability to reduce blood cholesterol in animals. In
addition, researchers validated SP-1000's ability, to clear clogged
arteries of atheroma; raise HDL, the good cholesterol; and reduce CK
enzyme elevations, a marker for heart suffering in animals.
   Additionally, researchers have identified SP-1000 as having a new
mechanism of action, i.e. it directly targets cholesterol in the blood
and appears to be active at the lowest dose tested, which could
suggest minimal side effects if tested in people.
   SP 1000 was discovered by researchers from Georgetown University
and is exclusively licensed to Samaritan. SP-1000's effect in reducing
circulating cholesterol levels was validated with two
hypercholesterolemia animal studies, one with ApoE knockout mice and
another with guinea pigs.
   Previously, on March 28, 2006 Samaritan announced that new
preclinical data from animal studies showed SP-1000 reduces
cholesterol. Upon further analysis of scientific data from these
animal studies, Samaritan found new claims to protect with a new
provisional U.S. patent application.
   Dr. Greeson, CEO of Samaritan stated, "Although we feel extremely
positive, I need to express a cautionary optimism in that animal
studies do not necessarily mean SP-1000 will work in people. It does
validate our original thesis as to how we think this drug works. In
addition, animal studies are enough to start looking to out-license
SP-1000 to a major pharmaceutical and/or perform additional
preclinical trials in preparation to file an IND with the FDA to
investigate SP-1000 in people."

   Samaritan Pharmaceuticals: "We LIV....to Save Lives."

   Samaritan is a small-cap Biotech, driven to discover, develop and
commercialize innovative therapeutics' for AIDS, Alzheimer's, Cancer
and Heart disease patients. Look at www.samaritanpharma.com. Please
register on Website so we can notify you of upcoming conference calls,
news and events.

   Disclaimer

   The company disclaims any information that is created by an
outside party and endorses only information that is communicated by
its press releases, filings and Website. This news release contains
forward-looking statements that reflect management's current beliefs
about the potential for its drug candidates, science and technology.
However, as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development and
regulatory review. There are no guarantees that products will prove to
be commercially successful. For additional information about the
factors that affect the company's business, please read the company's
latest Form 10-K filed April 15, 2005. The company undertakes no duty
to update forward-looking statements.